Skip to main content

Advertisement

SpringerLink
Log in

Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is complicated by disturbances of mineral and bone metabolism which start early in the course of the disease. It has long been assumed that high turnover bone lesions induced by secondary hyperparathyroidism are the predominant type of renal osteodystrophy from the start. However, there is increasing evidence in favor of the view that in early CKD stages low bone turnover is prevailing, with adynamic bone disease being the predominant form. Since serum parathyroid hormone levels increase progressively early on, and the most probable explanation is resistance to the skeletal action of this hormone. An early inhibition of the Wnt pathway with an increase in sclerostin and other inhibitors of Wnt signaling may be involved. Finally, a variety of other uremic toxins such as indoxyl sulfate and phosphate may play an important role in the pathogenesis of the low turnover bone disease observed in early stages of CKD. The optimal strategies to prevent and to treat adynamic bone disease in incipient CKD yet need to be defined. Targeting uremic toxins such as sclerostin, phosphate, and indoxyl sulfate may be relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kidney Disease-Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl:S1–S130

  2. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1–201

    Google Scholar 

  3. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB (2008) K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 73:771–777

    Article  CAS  PubMed  Google Scholar 

  4. Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376

    Article  PubMed  Google Scholar 

  5. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D’Haese PC, Drueke TB, Du H, Manley T et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67:559–566

    Article  PubMed  Google Scholar 

  6. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV (1993) The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int 43:436–442

    Article  CAS  PubMed  Google Scholar 

  7. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F (1996) Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transpl 11:813–819

    Article  CAS  Google Scholar 

  8. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J et al (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Barreto FC, Barreto DV, FernandesCanziani ME, Tomiyama C, Higa A, Mozar A, Glorieux G, Vanholder R, Massy ZA, BarbosaDeCarvalho A (2014) Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J Braz Nefrol 36:289–296

    Google Scholar 

  10. Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM et al (2016) Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int 90:648–657

    Article  CAS  PubMed  Google Scholar 

  11. Lafage-Proust MH, Combe C, Barthe N, Aparicio M (1999) Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab 84:512–519

    Article  CAS  PubMed  Google Scholar 

  12. Graciolli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, Sabbagh Y, Carvalho AB, Jorgetti V, Elias RM, Schiavi S, Moysés RM (2017) The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. doi:10.1016/j.kint.2016.12.029

    PubMed  Google Scholar 

  13. Drueke TB, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89:289–302

    Article  PubMed  Google Scholar 

  14. Cosman F, Morgan DC, Nieves JW, Shen V, Luckey MM, Dempster DW, Lindsay R, Parisien M (1997) Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 12:958–966

    Article  CAS  PubMed  Google Scholar 

  15. Yan L, Schoenmakers I, Zhou B, Jarjou LM, Smith E, Nigdikar S, Goldberg GR, Prentice A (2009) Ethnic differences in parathyroid hormone secretion and mineral metabolism in response to oral phosphate administration. Bone 45:238–245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA (2014) CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol 25:1760–1773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C et al (2012) Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27:1757–1772

    Article  CAS  PubMed  Google Scholar 

  18. Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, Gattone VH 2nd, Allen MR (2015) Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 30:499–509

    Article  PubMed  Google Scholar 

  19. Bover J, Jara A, Trinidad P, Rodriguez M, Felsenfeld AJ (1999) Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus. Bone 25:279–285

    Article  CAS  PubMed  Google Scholar 

  20. Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, Graciolli FG, Oliveira EC, Liu S, Sabbagh Y et al (2013) Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease—role of sclerostin? PLoS One 8:e79721

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V et al (2012) Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transpl 27:505–513

    Article  CAS  Google Scholar 

  22. Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H, Maruyama T, Fukagawa M (2013) p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 56:347–354

    Article  CAS  PubMed  Google Scholar 

  23. Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, Yamato H, Kurokawa K, Fukagawa M (2007) Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 71:738–743

    Article  CAS  PubMed  Google Scholar 

  24. Mozar A, Louvet L, Godin C, Mentaverri R, Brazier M, Kamel S, Massy ZA (2012) Indoxyl sulphate inhibits osteoclast differentiation and function. Nephrol Dial Transpl 27:2176–2181

    Article  CAS  Google Scholar 

  25. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M (2006) Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transpl 21:2768–2774

    Article  CAS  Google Scholar 

  26. Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M (2013) Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease. Bone 57:477–483

    Article  CAS  PubMed  Google Scholar 

  27. Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease—mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. doi:10.1016/j.bone.2017.01.023

    Google Scholar 

  28. Metzinger-Le Meuth V, Burtey S, Maitrias P, Massy ZA, Metzinger L (2017) microRNAs in the pathophysiology of CKD-MBD: Biomarkers and innovative drugs. Biochim Biophys Acta 1863:337–345

    Article  CAS  PubMed  Google Scholar 

  29. Prisby R, Guignandon A, Vanden-Bossche A, Mac-Way F, Linossier MT, Thomas M, Laroche N, Malaval L, Langer M, Peter ZA et al (2011) Intermittent PTH(1–84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J Bone Miner Res 26:2583–2596

    Article  CAS  PubMed  Google Scholar 

  30. Sun CY, Chang SC, Wu MS (2012) Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 81:640–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Towler DA (2011) Skeletal anabolism, PTH, and the bone-vascular axis. J Bone Miner Res 26:2579–2582

    Article  PubMed  PubMed Central  Google Scholar 

  32. Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, Wang S, Xiao T, Xu X, He T et al (2015) Klotho protects against indoxyl sulphate-induced myocardial hypertrophy. J Am Soc Nephrol 26:2434–2446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Carvalho C, Alves CM, Frazao JM (2016) The role of bone biopsy for the diagnosis of renal osteodystrophy: a short overview and future perspectives. J Nephrol 29:617–626

    Article  PubMed  Google Scholar 

  34. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, Shroff R, Thadhani RI, Tonelli MA, Kasiske BL et al (2015) Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int 87:502–528

    Article  PubMed  Google Scholar 

  35. Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G et al (2016) Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J Nephrol 29:71–78

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Ambroise Paré Hospital, APHP, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University, UVSQ), 9 avenue Charles de Gaulle, 92104, Boulogne Billancourt and Villejuif Cedex, France

    Ziad Massy

  2. Inserm U-1018, Team 5, Paris-Sud University (UPS) and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University, UVSQ), Villejuif, France

    Ziad Massy & Tilman Drueke

Authors
  1. Ziad Massy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tilman Drueke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ziad Massy.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Massy, Z., Drueke, T. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease. J Nephrol 30, 629–634 (2017). https://doi.org/10.1007/s40620-017-0397-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-017-0397-7

Keywords

Search

Navigation